Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2020-06-30 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
FDA grants breakthrough designation for TLX250-CDx product 1
Regulatory Filings Classification · 95% confidence The document is a company announcement from Telix Pharmaceuticals Limited dated 1st July 2020. It announces that the FDA has granted Breakthrough Therapy designation for a renal cancer imaging product. The content focuses on regulatory status and development progress of a product, with no financial data, no detailed financial statements, no voting results, no management changes, no earnings data, and no detailed investor presentation. The document is relatively short (3959 characters) and reads as a news release or regulatory announcement about a clinical development milestone. It does not contain or reference an annual or interim report, audit report, or any other formal financial filing. It is not a report publication announcement since it does not mention any report being attached or published. The nature of the content fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about FDA designation and development status of a product, which is typical for RNS filings. Therefore, the correct classification is Regulatory Filings (RNS).
2020-06-30 English
Recommencement of ZIRCON Phase III Trial Recruitment in EU 1
Regulatory Filings Classification · 95% confidence The document is an announcement from Telix Pharmaceuticals Limited about the recommencement of patient recruitment for their ZIRCON Phase III clinical trial. It provides details about the trial status, locations, and company background. There are no financial statements, regulatory certifications, voting results, or management changes. The document is relatively short (3992 characters) and serves as a corporate update on clinical trial progress rather than a financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about clinical trial activity, which is best classified under Regulatory Filings (RNS) as a miscellaneous announcement that does not fit other specific categories.
2020-06-17 English
Update on New Drug Application for Prostate Cancer Imaging 1
Regulatory Filings Classification · 95% confidence The document is an update from Telix Pharmaceuticals Limited regarding the progress of a New Drug Application (NDA) for a prostate cancer imaging product. It provides information about recent data, expected submission timelines, and company background. The document is relatively short (3500 characters) and serves as a progress update rather than a detailed financial or regulatory report. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention the release or availability of a report but rather an update on a regulatory submission process. The content fits best under a general regulatory announcement category related to company progress on regulatory filings and product development. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-06-09 English
Presentation to Jefferies Virtual Healthcare Conference 21 pages 14.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Telix Pharmaceuticals Limited at the Jefferies Healthcare Conference in June 2020. It contains company overview, product pipeline, market opportunities, clinical trial information, and strategic plans. The content is structured as a slide deck with multiple pages and images (omitted here), focusing on financial and strategic information for investors. There is no indication that this is an official annual or interim report, audit report, or regulatory filing. It is not a transcript of a call, nor a voting or dividend announcement. The document is clearly a presentation aimed at investors and analysts, providing detailed financial, strategic, and market information. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-06-03 English
Appointment of Dr Colin Hayward as Chief Medical Officer 2 pages 191.3KB
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of Dr. Colin Hayward as Chief Medical Officer at Telix Pharmaceuticals Limited. It details his background, role, and the transition of another executive to a non-executive role. There is no financial data, no report or presentation attached, and no mention of voting results or regulatory filings. The content focuses on a change in senior management, which fits the category of Board/Management Information (MANG). The document length is 4106 characters, which is relatively short and consistent with an announcement rather than a full report.
2020-06-01 English
Appendix 2A - shares issued on exercise of options 15 pages 229.8KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities such as options exercised or convertible securities converted. This type of document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of securities. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement but a formal regulatory filing to the exchange. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-05-31 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.